DUBLIN, Aug 12, 2021 /PRNewswire/ — The Global Cellular Immunotherapy Market Report 2021: Growth and Change from COVID-19 to 2030 report has been added to ResearchAndMarkets.com’s offer.
The global cellular immunotherapy market is expected to grow from: $2.74 billion in 2020 to $3.59 billion in 2021 at a compound annual growth rate (CAGR) of 31%. The market is expected to reach $6.73 billion in 2025 at a CAGR of 17%.
Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., and Roche.
The cellular immunotherapy market consists of revenues generated by the companies engaged in the development, manufacture and sale of cellular immunotherapy drugs. Cellular immunotherapy is also known as adoptive cell therapy, a form of treatment that uses the cells of the immune system to eliminate diseases, including non-Hodgkin’s lymphoma, cancer, and acute lymphoblastic leukemia.
The cellular immunotherapy market covered in this report is segmented by therapy into tumor-infiltrating lymphocyte (TIL) therapy; engineered T cell receptor (TCR) therapy; chimeric antigen receptor (CAR) T cell therapy; natural killer (NK) cell therapy. It is also segmented by primary indication in b-cell malignancies; prostate cancer; renal cell carcinoma; liver cancer; non-Hodgkin’s lymphoma; others and by use in prostate cancer; breast cancer; skin cancer; ovarian cancer; brain tumor; lung cancer; others.
The high cost of cellular immunotherapy is expected to hinder the cellular immunotherapy market growth. CAR-T therapy is a form of cellular immunotherapy and only two are approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is very unaffordable for a majority of patients, especially those on low incomes. The high cost of cellular immunotherapy discourages patients from opting for this drug, negatively affecting demand and the market.
Companies in the cellular immunotherapy market are focused on developing ready-to-use allogeneic therapies for new and improved cancer treatments. Ready-to-use allogeneic therapies are produced from donor cells rather than patient cells, as in the case of autologous therapy. Their non-customized nature offers advantages such as cost effectiveness, large scale, fast and quality control production.
For example, in Nov 2019Precision Biosciences, Inc., a biotechnology company, has developed a next-generation allogeneic CAR-T therapy and is conducting an ongoing trial of this therapy by creating the first ready-to-use allogeneic CAR-T therapy candidate, known as PBCAR0191 . This is in partnership with Servier, an international pharmaceutical company, and is primarily aimed at patients requiring advanced cancer treatment options.
In addition, in August 2020Acepodia, a US-based next-generation cell immunotechnology company, initiated a Phase 1 clinical trial evaluating ACE1702, an allogeneic, turn-key NK cell therapy for the treatment of solid tumors.
In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specializing in the development and commercialization of drugs used to treat aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both companies will continue their activities as ‘Adicet Bio’.
This merger is expected to help the companies advance allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specializing in the development of ready-to-use allogeneic gamma-delta T-cell therapies from Adicet for oncology and other indications.
Increasing research and successful clinical trials in the field of cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies focus on developing new cellular immunotherapies for the treatment of various diseases.
The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 compared to that in 2019 is expected to expand the landscape of cellular immunotherapy. Then generate higher revenues for the cellular immunotherapy market.
Main topics covered:
2. Cellular Immunotherapy Market Characteristics
3. Cellular Immunotherapy Market Trends and Strategies
4. Impact of COVID-19 on Cellular Immunotherapy
5. Market Size and Growth for Cellular Immunotherapy
5.1. Global Historic Cellular Immunotherapy Market, 2015-2020, $Billion
5.1.1. Market drivers
5.1.2. Restrictions on the market
5.2. Global Cellular Immunotherapy Forecast Market, 2020-2025F, 2030F, $Billion
5.2.1. Market drivers
5.2.2. Restrictions on the market
6. Market Segmentation for Cellular Immunotherapy
6.1. Global Cellular Immunotherapy Market, Segmentation by Therapy, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Tumor Infiltrating Lymphocytes (TIL) Therapy
Engineered T-cell receptor (TCR) therapy
Chimeric Antigen Receptor (CAR)
Natural Killer (NK) cell therapy
6.2. Global Cellular Immunotherapy Market, Segmentation by Primary Indication, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Renal cell carcinoma
6.3. Global Cellular Immunotherapy Market Segmentation by Application, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7. Regional and Country Market Analysis for Cellular Immunotherapy
7.1. Global Cellular Immunotherapy Market Split by Regions, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, USD Billion
7.2. Global Cellular Immunotherapy Market Breakdown by Country, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, USD Billion
Gilead Sciences Inc. (Kite Pharma)
Dendreon Pharmaceuticals LLC
JW CreaGene Co. Ltd
Green Cross Corp (GC Pharma)
For more information about this report, visit https://www.researchandmarkets.com/r/wotopz
Research and markets
Laura Wood, senior manager
For EST business hours, call +1-917-300-0470
For USA/CAN Toll Free Call +1-800-526-8630
For GMT office hours, please call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-cellular-immunotherapy-market-research-report-2021-companies-are-focusing-on-developing-off-the-shelf-allogeneic-therapies-for- new-and-improved-cancer-treatment-301354249.html
SOURCE Research and markets